1. Has your trust accepted or is it currently accepting manufacturer provision of free of charge drug stock between licensing and NICE funding? [Yes/No]
2. Has your trust accepted or is it currently accepting the following list of drugs in psoriasis:
Brodalumab [Kyntheum] [Yes/No]
Guselkumab [Tremfya] [Yes/No]
Ixekizumab [Taltz] [Yes/No]
Secukinumab [Cosentyx] [Yes/No]
3. Has your trust accepted or is it currently accepting the following list of drugs in Rheumatoid Arthritis:
Tofacitinib [Xeljanz] [Yes/No]
Baricitinib [Olumiant] [Yes/No]
Golimumab [Simponi] [Yes/No]
Certolizumab [Cimzia] [Yes/No]
Apremilast [Otezla] [Yes/No]
Tocilizumab [Ro Actemra] [Yes/No]
4. Has your trust accepted or is it currently accepting the following list of drugs in Ankylosing Spondylitis or Psoriatic Arthritis:
Secukinumab [Cosentyx] [Yes/No]
5. Has your trust accepted or is it currently accepting the following list of drugs in Ulcerative Colitis:
Golimumab [Simponi] [Yes/No]
6. If your trust has not accepted manufacturer provision of free of charge drug stock, what have been the reasons for this?
7. In future, will your trust be able to accept manufacturer provision of free of charge drug stock? [Yes/No]
8. What is the preferred distribution channel for the provision of free of charge drug stock?
Homecare [Yes/No]
Delivered directly to hospital/Trust [Yes/No]
Other (please provide details)
9. For how long is free of charge drug stock typically provided for each patient?
First dose [Yes/No]
First month [Yes/No]
First 3 months [Yes/No]
Other

Download response Drug stock. 300518